Delhi HC: Saying “Maro Sale Ko” During a Fight Alone Does Not by Itself Establish Intent to Kill  ||  Delhi HC Ordered Removal of Fake News About Judges’ London Badminton Event, Restrained its Sharing  ||  Bombay HC: Calling Police over Routine Transfers or External Complaints is Misconduct  ||  Delhi HC Upheld EC’s Decision Banning Political Ads in the Delhi Metro During Model Code of Conduct  ||  Delhi HC: In the Telegram Case Entire Social Media Platforms Can Be Blocked U/S 69A of the IT Act  ||  Supreme Court: Pedestrians' Right to Footpaths Cannot be Overridden by Motorists  ||  Supreme Court: Financier Cannot Seek Insurance For a Vehicle Surrendered by its Owner  ||  Madhya Pradesh High Court: Victims Must be Given a Hearing Even Before Closure Report Rejection  ||  Delhi HC: Payment of ‘Pagri’ Does Not Render Tenancy Non-Terminable, Allowing Eviction  ||  Ker HC Examined Whether Electro-Homeopathy Can be Practised Without Registration under Medical Laws    

Glenmark Settles Patent Litigation over Milnacipran Hydrochloride Tablets - (22 Dec 2015)

Glenmark Pharmaceuticals Inc., USA have entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, and Royalty Pharma Collection Trust to settle and dismissed outstanding patent litigation related to Glenmark's Abbreviated New Drug Application.

Tags : GLENMARK PHARMACEUTICALS INC   FOREST LABORATORIES   LLC   FOREST LABORATORIES HOLDINGS     ROYALTY PHARMA COLLECTION TRUST  

Share :        

Disclaimer | Copyright 2026 - All Rights Reserved